Coherus BioSciences, Inc.
General ticker "CHRS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $134.1M (TTM average)
Coherus BioSciences, Inc. follows the US Stock Market performance with the rate: 42.4%.
Estimated limits based on current volatility of 4.2%: low 1.20$, high 1.30$
Factors to consider:
- Total employees count: 228 (-25.5%) as of 2024
- Top business risk factors: Regulatory and compliance, Operational and conduct risks, Fundraising challenges, Labor/talent shortage/retention, Dispute risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.90$, 2.65$]
- 2025-12-31 to 2026-12-31 estimated range: [1.17$, 3.23$]
Financial Metrics affecting the CHRS estimates:
- Positive: with PPE of -2.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 5.98
- Negative: Operating cash flow per share per price, % of -12.05 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CHRS quotes
Long-term CHRS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $211.04MM | $257.24MM | $266.96MM |
| Operating Expenses | $467.92MM | $460.44MM | $378.63MM |
| Operating Income | $-256.88MM | $-203.20MM | $-111.67MM |
| Non-Operating Income | $-34.87MM | $-35.07MM | $140.17MM |
| Interest Expense | $32.47MM | $40.54MM | $27.16MM |
| R&D Expense | $199.36MM | $109.44MM | $93.34MM |
| Income(Loss) | $-291.75MM | $-238.27MM | $28.51MM |
| Taxes | $0.00MM | $-0.38MM | $0.00MM |
| Profit(Loss)* | $-291.75MM | $-237.89MM | $28.51MM |
| Stockholders Equity | $-137.42MM | $-193.43MM | $-131.99MM |
| Inventory | $38.79MM | $62.60MM | $70.09MM |
| Assets | $480.85MM | $629.60MM | $448.53MM |
| Operating Cash Flow | $-241.12MM | $-174.88MM | $-20.44MM |
| Capital expenditure | $2.04MM | $0.29MM | $0.00MM |
| Investing Cash Flow | $-166.85MM | $144.64MM | $230.32MM |
| Financing Cash Flow | $54.33MM | $69.60MM | $-186.97MM |
| Earnings Per Share** | $-3.76 | $-2.53 | $0.25 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.